Lund, Sweden, 2014-05-15 08:37 CEST (GLOBE NEWSWIRE) --
EXINI has completed delivery of the software cardioREPO 1.0, the Japanese version of EXINI heart, to FUJIFILM RI Pharma in accordance with last year’s agreement. FUJIFILM RI Pharma will now proceed to deliver systems to hospitals throughout Japan and EXINI receives a significant milestone payment.
The software EXINI heart (cardioREPO on the Japanese market) is EXINI’s second product to be launched onto the Japanese market. Last August, EXINI and FUJIFILM RI Pharma agreed to develop EXINI heart specifically for Japanese purposes. This version includes several new and unique features beneficiary to the world market. Last year’s five-year agreement includes licensing, service & support as well as a no-limit bonus. The agreement also includes a continuation of the contract for EXINI bone BSI for the Japanese market (for additional information regarding the agreement between EXINI and FUJIFILM RI Pharma, please visit www.exini.com/press-media/ 27 August 2013).
“The partnership with EXINI Diagnostics has proven itself excellent, yet again. They always deliver on time and in accordance to what has been promised. We are excited to introduce cardioREPO to Japanese hospitals” , comments Toshiya Morita, Deputy General Manager, Sales & Marketing Division, FUJIFILM RI Pharma
“cardioREPO is a new unique tool for Cardiologists and Nuclear Medicine Doctors equipped with functions and with a performance not to be found in other software solutions. Its computer-assisted diagnosis based on Artificial Neural Network and the new regional analyses, will be put to effective use both in research and clinical practices“ , explains Dr. Kenichi Nakajima, Kanazawa University
“The successful development of cardioREPO and its new features, was made possible thanks to an excellent collaboration with Kanazawa University and with FUJIFILM RI Pharma. We continue to fulfill our commitments according to the contract and we look forward to the launch of cardioREPO in Japan” , comments Magnus Aurell, CEO, EXINI Diagnostics AB.
“We are proud to be able to provide this advanced software to Japanese physicians and I am convinced it will prove itself an effective tool improving both diagnosis and treatment of patients.” comments Yoshirou Kumano, President and CEO, FUJIFILM RI Pharma
For more information, please contact: Magnus Aurell, CEO Phone: +46 46 286 54 25 E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ) EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 600 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkomission AB acts as Certified Adviser.
________________________________________________________________________ EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com
